Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY3556050

Small molecule · developed by ELI LILLY &

Phase 2 Most advanced trial
LLY Developer

What is LY3556050?

LY3556050 is an investigational small-molecule drug studied in Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain.

At a glance

Drug type
Small molecule
Therapy area
Musculoskeletal
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

Conditions studied

Chronic Low-back PainDiabetic Neuropathic PainOsteoarthritis, Knee

More from ELI LILLY &

Follow LLY, the company behind LY3556050

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.